Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 10/2015

01-10-2015 | Lung Cancer (HA Wakelee, Section Editor)

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

Authors: Hirva Mamdani, MD, Shadia I. Jalal, MD, Nasser Hanna, MD

Published in: Current Treatment Options in Oncology | Issue 10/2015

Login to get access

Opinion statement

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.
Literature
1.
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940–5.CrossRefPubMed
2.
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87(3):198–205.CrossRefPubMed
3.
Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med. 1996;125(9):723–9.CrossRefPubMed
4.
Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452–60.PubMedCentralCrossRefPubMed
5.
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692–9.PubMed
6.
Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.CrossRefPubMed
7.
Vokes EE, Herndon 2nd JE, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20(20):4191–8.CrossRefPubMed
8.
Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28(23):3739–45.CrossRefPubMed
9.
Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299–306.CrossRefPubMed
10.
Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011;29(23):3120–5.PubMedCentralCrossRefPubMed
11.••
Park K, Ahn YC, Ahn JS, Ahn M-J, Kim J-H, Cho EK, et al. A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN). ASCO Meeting Abstracts. 2014;32(15):7500. A phase III trial evaluating the role of consolidation chemotherapy with cisplatin plus docetaxel after concurrent chemoradiotherapy with weekly cisplatin plus docetaxel. The PFS and OS were not statistically different and patients receiving consolidation therapy experienced more toxicities.
12.•
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99. A randomized phase III trial of standard dose versus high dose radiotherapy in combination with concurrent and consolidation chemotherapy with or without cetuximab. Median OS was better with 60Gy radiation and the addition of cetuximab provided no additional survival benefit.CrossRefPubMed
13.••
Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015;33(6):567–74. This is the largest retrospective analysis comparing etoposide plus cisplatin or carboplatin plus paclitaxel with concurrent radiotherapy in stage III NSCLC from Veterans Health Administration. The data suggest that any difference in survival outcomes between the two regimens is likely to be small or non-existent.CrossRefPubMed
14.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.CrossRefPubMed
15.
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMed
16.
Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009;10(3):193–8.CrossRefPubMed
17.
Senan S, Brade AM, Wang L, Vansteenkiste JF, Dakhil SR, Biesma B, et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). ASCO Meeting Abstracts. 2015;33(15):7506.
18.
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–62.CrossRefPubMed
19.
Hasegawa Y, Miura D, Ota T, Yokouchi J. Phase I study of bi-weekly nab-paclitaxel and carboplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer. ASCO Meeting Abstracts. 2015;33(15):7529.
20.
Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi 3rd AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13(8):1880–92.PubMed
21.
Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23(25):5883–91.CrossRefPubMed
22.
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.CrossRefPubMed
23.
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefPubMed
24.
Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J, Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53(6):992–8.CrossRefPubMed
25.
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330(3):153–8.CrossRefPubMed
26.
Roth JA, Fossella F, Komaki R, Ryan MB, Putnam Jr JB, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86(9):673–80.CrossRefPubMed
27.•
Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–902. A phase III trial of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous NSCLC showing improved OS with maintenance therapy compared to placebo.CrossRefPubMed
28.
Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol. 2008;26(35):5755–60.CrossRefPubMed
29.•
Huber RM, Engel-Riedel W, Kollmeier J, Andreas S, Staar S, Klautke G, et al. GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): final results of a phase (ph) III study. ASCO Meeting Abstracts. 2012;30(15):7001. A phase III GILT CT-RT evaluating role of consolidation chemotherapy with cisplatin plus vinorelbine following chemoradiation with cisplatin and oral vinorelbine No statistically significant difference was found in PFS or OS with consolidation chemotherapy.
30.••
Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2013;8(9):1181–9. A pooled analysis of the literature including 41 phase II or III trials evaluating the role of consolidation (either continuation consolidation or switched consolidation) chemotherapy reported no improvement in OS with either consolidation approach.CrossRefPubMed
31.
Vokes EE, Herndon 2nd JE, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25(13):1698–704.CrossRefPubMed
32.•
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–73. A randomized phase 3 trial of ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV NSCLC after disease progression on platinum-based therapy showing improved survival with ramicirumab based therapy.CrossRefPubMed
33.•
Wozniak AJ, Moon J, Thomas CR, Jr., Kelly K, Mack PC, Gaspar LE, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (nsc-704865) in patients with inoperable locally advanced stage iii non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer. 2015. A pilot study evaluating the role of bevacizumab plus docetaxel as consolidation therapy after initial chemoradiation in locally advanced non-small cell lung cancer. Bevacizumab was associated with fatal hemoptysis in a high-risk group of patients
34.
Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol. 2010;28(1):43–8.CrossRefPubMed
35.
Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010;102(12):859–65.PubMedCentralCrossRefPubMed
36.•
Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012;30(6):616–22. A randomized phase III study evaluating the role of thalidomide in combination with chemoradiation in stage III NSCLC which showed increased toxicities but no survival benefit with addition of thalidomide to chemoradiation.PubMedCentralCrossRefPubMed
37.
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6.CrossRefPubMed
38.
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–31.CrossRefPubMed
39.
Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13(1):33–42.CrossRefPubMed
40.
Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res. 2007;13(22 Pt 1):6555–60.CrossRefPubMed
41.
Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007;67(11):5267–74.CrossRefPubMed
42.•
Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Mol Cancer Ther. 2013;12(5):696–704. This paper provides pre-clinical data indicating that ALK inhibitor crizotinib acts as a radiosensitizer in cells harboring the EML4-ALK fusion, providing a rationale for a clinical trial combining ALK inhibitor with radiation in the NSCLCs harboring ALK gene rearrangement.PubMedCentralCrossRefPubMed
43.
McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene. 2003;22(37):5866–75.CrossRefPubMed
44.
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.PubMedCentralCrossRefPubMed
45.••
Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2(9):831–8. This paper explains the concept of combining radiotherapy and immunotherapy, especially immune checkpoint inhibitors in the treatment of solid tumors along with currently available preclinical and clinical data to support this approach.CrossRefPubMed
46.
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31.PubMedCentralCrossRefPubMed
47.
Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.PubMedCentralCrossRefPubMed
48.•
Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams M, et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer immunology research. 2015. This paper highlights the important phenomenon of PD-1 mediated blunting of heightened anti-tumor immune response after radiotherapy in preclinical models, thereby indicating that combination of radiotherapy and PD-1 blockade may be a potential treatment strategy for malignant tumors.
49.
Lim SH, Chua W, Cheng C, Descallar J, Ng W, Solomon M, et al. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. Anticancer Res. 2014;34(11):6505–13.PubMed
50.
Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rodel F, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110(2):501–9.PubMedCentralCrossRefPubMed
51.
Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91.CrossRefPubMed
52.•
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59–68. This is a phase III randomized trial evaluating the role of Tecemotide (L-BLP25), a MUC1-antigen specific cancer immunotherapy, as consolidation therapy after chemoradiation in locally advanced NSCLC. In this study, a subset analysis of patients treated with concurrent chemoradiation showed improved overall survival with tecemotide.CrossRefPubMed
Metadata
Title
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration
Authors
Hirva Mamdani, MD
Shadia I. Jalal, MD
Nasser Hanna, MD
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 10/2015
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-015-0364-2

Other articles of this Issue 10/2015

Current Treatment Options in Oncology 10/2015 Go to the issue

Lung Cancer (HA Wakelee, Section Editor)

Management of Dermatologic Complications of Lung Cancer Therapies

Lung Cancer (HA Wakelee, Section Editor)

Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress

Lung Cancer (HA Wakelee, Section Editor)

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Targeted Therapy in Biliary Tract Cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits